Therapy with DNA damaging drugs of a small number of non-metastatic and metastatic colorectal cancer patients ISSN 2753-8176 (online)
Therapy with DNA damaging drugs of a small number of non-metastatic and metastatic colorectal cancer patients Ana Pedro (1) 1. Gwyntwr1386 Pharmacy, Regus Chester Business Park, Heronsway,Chester CH4 9QR, United Kingdom info@gwyntwr1386.com Introduction and results Colorectal cancer (CRC) is the third most common malignancy and the second most deadly cancer, inducing estimated 1.9 million incidence cases and 0.9 million deaths worldwide in 2020 (1). Each year, approximately, 230,000 patients are treated with adjuvant chemotherapy (AT) (2) . Nine patients with non-metastatic (NM) and metastatic (M) CRC were treated with 5-fluorouracil (5-FU)/leucovorin (LV) (LV5FU) regimen (3), 3 patients with M disease with FOLFOX (folinic acid (leucovorin, FOL), fluorouracil (5-FU, F), and oxaliplatin (Eloxatin, OX) (4) and 2 patients with NM and M disease were treated with XELOX regimen (capecitabine (trade name Xeloda) combined with oxaliplatin (5) (tables 1 and 2). All the patients...